NR-55343来自SARS相关冠状病毒2的刺突糖蛋白(稳定）,带有C末端组氨酸标签的D614G变体,来自HEK293细胞(蛋白质）的重组
产品图片
货号/SKU
NR-55343
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55343?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, D614G Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, D614G Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells|-80°C (Note: Storage at warmer temperatures is not recommended due to a low bioburden.)|BPS BioscienceAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, D614G Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55343.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), D614G variant was produced in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55343 lacks the signal sequence (residues 1 to 15) and contains 1195 residues (ectodomain; S1 + S2) of the SARS-CoV-2 S glycoprotein; the recombinant protein was modified to remove the polybasic S1/S2 cleavage site (RRAR to A; residues 682 to 685), stabilized with a pair of mutations (K986P and V987P, wild type numbering) and includes a thrombin cleavage site, T4 foldon trimerization domain and C-terminal hexa-histidine tag. NR-55343 is a variant of SARS-CoV-2 which contains the D614G mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55343 has a theoretical molecular weight of 137,000 daltons. The crystal structure for trimeric S glycoprotein from the SARS-CoV-2 D614G variant has been solved at 3.46 ? resolution (PDB: 6XS6).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The D614G mutation is common to the current variants of interest and concern identified by the Centers for Disease Control and Prevention (CDC). This mutation was one of the first documented in the USA in the initial stages of the pandemic after having initially circulated in Europe. Some evidence suggests that variants with the D614G mutation are more infectious than wild-type.
Each vial contains approximately 50 ?g of purified recombinant protein in 8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl and 20% glycerol.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), D614G variant was produced in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55343 lacks the signal sequence (residues 1 to 15) and contains 1195 residues (ectodomain; S1 + S2) of the SARS-CoV-2 S glycoprotein; the recombinant protein was modified to remove the polybasic S1/S2 cleavage site (RRAR to A; residues 682 to 685), stabilized with a pair of mutations (K986P and V987P, wild type numbering) and includes a thrombin cleavage site, T4 foldon trimerization domain and C-terminal hexa-histidine tag. NR-55343 is a variant of SARS-CoV-2 which contains the D614G mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55343 has a theoretical molecular weight of 137,000 daltons. The crystal structure for trimeric S glycoprotein from the SARS-CoV-2 D614G variant has been solved at 3.46 ? resolution (PDB: 6XS6).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The D614G mutation is common to the current variants of interest and concern identified by the Centers for Disease Control and Prevention (CDC). This mutation was one of the first documented in the USA in the initial stages of the pandemic after having initially circulated in Europe. Some evidence suggests that variants with the D614G mutation are more infectious than wild-type.
Each vial contains approximately 50 ?g of purified recombinant protein in 8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl and 20% glycerol.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
在人胚胎肾HEK293细胞中产生来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的穗的重组形式，来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2），D614G变体.通过亲和层析纯化. NR-55343缺少信号序列（残留物1至15）并含有SARS-COV-2S糖蛋白的1195个残基（Ectodomain1 + S2）;修饰重组蛋白以除去多元的S1 / S2切割位点（RRAR至A;残留物682至685），用一对突变稳定（K986P和V987P，野生型编号），并包括凝血酶切割位点，T4 Folcon三聚体化结构域和C末端六甲基 - 组氨酸标签. NR-55343是SARS-COV-2的变体，其含有与SARS-COV-2参考序列（Genpept：）. NR-55343具有137,000道尔顿的理论分子量.来自SARS-COV-2 D614G变体的三聚糖蛋白的晶体结构已经解决了3.46埃分辨率（PDB： 6xs6 ）.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜. D614G突变对于当前感兴趣的变体和疾病控制中心（CDC）的中心鉴定的疑虑是常见的.这种突变是在欧洲最初循环之后在大流行之后的首次记录在美国的突变之一.有些证据表明，与D614G突变的变体比野生型更传染.
每个小瓶在8mM磷酸pH 7.4,110mM NaCl，2.2mM KCl和20％甘油中含有大约50μg的纯化重组蛋白.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01